Health Care • Biotechnology: Pharmaceutical Preparations
$3.04 ▲ +0.28
(+10.15%)
MKT CAP: $247.0M • VOL: 3.11M
52W L $1 52W H $5
ROARABLE / RQD
D- • 39/100
PIOTROSKI
1 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$3
MEDIAN
$3
MEAN
$3
HIGH
$4
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ELDN TAPE
ELDN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $3.68 | $3.50 | 2025-02-14 | $2.77 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $3.83 | $3.59 | 2025-02-06 | $2.86 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $3.47 | $3.34 | 2025-01-29 | $2.92 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $3.10 | — | 2025-01-17 | $2.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $2.68 | $2.89 | 2025-01-09 | $2.71 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $3.62 | $3.16 | 2024-12-18 | $2.64 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $2.95 | $3.07 | 2024-12-04 | $2.83 | -4.3% | 48% | C |